Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses

Journal of Clinical Endocrinology and Metabolism

Volumn 76, Issue 3, 1993, Pages 752-756

  Boyle, Patrick J ^a   Justice, Keith ^a   Krentz, Andrew J ^a   Nagy, Roger J ^a   Schade, David S ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE; GLIPIZIDE; GLUCOSE; OCTREOTIDE; SULFONYLUREA;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG OVERDOSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; DIAZOXIDE; FEMALE; GLUCOSE; HUMAN; HYPERINSULINISM; HYPOGLYCEMIA; INFUSIONS, INTRAVENOUS; MALE; OCTREOTIDE; OSMOLAR CONCENTRATION; OVERDOSE; PEPTIDES; SULFONYLUREA COMPOUNDS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027457178     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.76.3.8445035     Document Type: Article

References (35)

1. Kennedy DL, Piper JM, Baum C. 1988 Trends in use of oral hypoglycemic agents, 1964-1986. Diabetes Care. 11:558-562.
2. Jennings AM, Wilson RM, Ward JD. 1989 Symptomatic hypoglycemia in N1DDM patients treated with oral hypoglycemic agents. Diabetes Care. 12:203-208.
3. Litovitz TL, Bailey KM, Schmitz BF, Holm KC, Klein-Schwartz W. 1990 Annual report of the american association of poison control centers national data collection system. Am J Emerg Med. 9:461-482.
4. Campbell IW. 1985 Metformin and the sulfonylureas: the comparative risk. In: Pfeiffer EF, Lipsett MB, eds. Hormone and metabolic research, Suppl Ser. New York: Thieme-Verlag; vol 15:105-111
5. Berger W, Caduff F, Pasquel M, Rump A. 1965 Die relative Häufigkeit der schweren Sulfonyhamstoff-hypoglykamie inden letzten 25 Jahren in der Schweiz. Schweiz Med Wochenschr. 116:145-151.
6. Dowd AL. 1992 The physicians desk reference, 46th ed. Montvale: Medical Economics Data; pp 1952-1954.
7. Ferner RE, Neil HAW. 1988 Sulphonylureas and hypoglycaemia. Br Med J. 296:949-950.
8. Grodsky GM, Epstein GH, Fanska R, Karam JH. 1977 Pancreatic action of the sulfonylureas. Fed Proc. 36:2714-2719.
9. Seltzer HS. 1989 Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am. 18:168-171.
10. Asplund K, Wiholm BE, Lithner F. 1983 Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 24:412-411.
11. Drash A, Kenny F, Field J, Blizzard R, Langs H, Wolff F. 1968 The therapeutic application of diazoxide in pediatric hypoglycemic states. Ann NY Acad Sei. 150:337-354.
12. Johnson SF, Schade DS, Peake GT. 1977 Chlorpropamide-induced hypoglycemia: successful treatment with diazoxide. Am J Med. 63:799-804.
13. Pfeiffer MA, Wolter CF, Samols E. 1978 Management of chlorpropamide induced hypoglycemia with diazoxide. South Med J. 71:606-608.
14. Jocobs RF, Nix RA, Paulus TE, Kiel EA, Fisher RH. 1978 Intravenous infusion of diazoxide in the treatment of chlorpropamide induced hypoglycemia. J Pediatr. 93:801-803.
15. Meatherall RC, Green PT, Kenick S, Donen N. 1981 Diazoxide in the management of chlorpropamide overdose. J Anal Toxicol. 5:287-291.
16. Jeffrey WH, Graham EM. 1983 Treatment of chlorpropamide overdose with diazoxide. Drug Intell Clin Pharmacol. 17:372-374.
17. Krentz AJ, Boyle PJ, Schade DS. 1991 Octreotide: a long-acting inhibitor of endogenous hormone secretion for investigations of human metabolism [Abstract]. Clin Res. 39(Suppl 1):55A.
18. Nakagawa S, Nakayama H, Sasaki T, et al. 1973 A simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes 22:590-600
19. Ensinck JW. 1983 Immunoassays for glucagon. In: Lefebvre P, ed. Glucagon handbook of experimental pharmacology. New York: Springer-Verlag; vol 66:203-221.
20. Schalch DS, Parker ML. 1964 A sensitive double antibody immunoassay for human growth hormone in plasma. Nature. 203:1141-1142.
21. Shah SD, Clutter WE, Cryer PE. 1985 External and internal standards in the single isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. J Lab Clin Med. 106:624-629.
22. SAS Institute Inc 1988 SAS/STAT® users guide release, 6.03 ed. Cary: SAS Institute.
23. Palatnick W, Meatherall RC, Tenenbein M. 1991 Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med. 151:1859-1862.
24. Kutz K, Nüesch E, Rozenthaler J. 1986 Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol. 21:65-72.
25. Reichlin S. 1983 Somatostatin (medical progress, two part series). N Engl J Med. 309:1495-1501, 1556-1563.
26. Longnecker SM. 1988 Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intell Clin Pharmacol. 22:99-106.
27. Rizza RA, Cryer PE, Gerich JE. 1979 Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation: effects of somatostatin and combined a- and d-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest. 64:62-71.
28. Samols E, Tyler J, Mialhe P. 1969 Suppression of pancreatic glucagon release by the hypoglycemic sulfonylureas. Lancet. 1:174.
29. Grodsky GM, Epstein GH, Fanska R, Karam JH. 1977 Pancreatic action of the sulfonylureas. Fed Proc. 36:2714-2719.
30. Phillips RE, Looareesuwan S, Bloom SR, et al. 1986 Effectiveness of SMS 201-995, a synthetic long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia. Lancet. 1:713-714.
31. Hearn PR, Ahmed M, Woodhouse NJY. 1988 The use of SMS 201-995 (somatostatin analogue) in insulinomas. Horm Res. 29:211-213.
32. Delemarre-van de Waal HA, Veldkamp IJM, Schrander-Stumpel CTRM. 1987 Long-term treatment of an infant with nesidioblastosis using a somatostatin analogue. N Engl J Med. 316:222-223.
33. Davies Miller M, Turner SJ, Goodship THJ, et al. 1986 Effects of somatostatin analogue SMS 201-995 in normal man. Clin Endocrinol (Oxf). 24:665-674.
34. Eaton RP, Schade DS. 1980 The effect of diazoxide-induced hormonal secretion on plasma triglyceride concentration in the rat. Diabetologia. 18:301-306.
35. Brown NF, Porter J, Ryder D, Branch RA. 1991 Caffeine potentiates the renin response to diazoxide in man. Evidence for a regulatory role of endogenous adenosine. J Pharmacol Exp Ther. 256:56-61.